Does the use of Rablidence lead to increased risk of fractures?
Several studies in adults suggest that treatment with Rablidence may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist or spine. The risk of fracture was increased in patients who received high dose. High dose can mean multiple daily doses, and long-term therapy (a year or longer).